Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth.
J Exp Clin Cancer Res
; 42(1): 25, 2023 Jan 20.
Article
in En
| MEDLINE
| ID: mdl-36670508
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
J Exp Clin Cancer Res
Year:
2023
Document type:
Article
Affiliation country: